BACKGROUND AND PURPOSE
Esophageal squamous cell carcinoma (ESCC) is one of the major subtypes
of esophageal cancer. More than half of the ESCC patients in the world
are in China, and the 5-year survival rate is less than 10%. As a new
oral proteasome inhibitor, ixazomib has shown strong therapeutic effect
in many solid tumors. In this study, we aimed to investigate the effects
of ixazomib on the proliferation inhibition and apoptosis of ESCC
cells.